TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00002832

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Subcutaneously (SQ) daily every 12 hours starting 2-4 days prior to first PBSC collection then daily starting 1 day after PBSC infusion until blood counts recover.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: IV daily on day -2, then orally once dose is tolerable, dose may be escalated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: IV for 6 hours every 12 hr for 5 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Stem cell infusion on Day 0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Peripheral blood stem cells (PBSC) are administered 5 days after last dose of decitabine.
Study: NCT01896401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InSeal's Vascular Closure Device
Study: NCT02919722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: The majority of each study session will be spent engaging in music therapy: playing live music with a music therapist with the help of an occupational therapist. At the beginning and end of each session subjects will complete 2 assessments.
Study: NCT01217008

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRNOPC1
Description: One injection of 2 million GRNOPC1 cells.
Study: NCT02841176

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Participants will start monthly Golimumab after their baseline visit
Study: NCT00333554

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA Treatment
Description: DHA study treatment given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food) depending on age of child.
Study: NCT03513757

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol 2 mg/kg at start of procedure; 2 mg/kg for movement, 150-300 mcg/kg/minute propofol infusion if movement persists
Study: NCT00333554

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for DHA
Description: Study placebo given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food)depending on age of child.
Study: NCT02088723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Head of bed elevation
Description: head of bed elevation elevation the head of the bed with 15 cm (head of bed elevation) and compare the apnea-hypopnea index with the standard polysomnography
Study: NCT01841645

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: CLA depletion-repletion
Study: NCT03868098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crisaborole 2%
Description: Crisaborole ointment 2% (application rate A, B, C) for 15 days (double blind)
Study: NCT03513757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: propofol 2 mg/kg at start of procedure; 2 mg/kg for movement, 150-300 mcg/kg/minute propofol infusion if movement persists

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: single dose dexmedetomidine administered at start of sedation in the propofol-dexmedetomidine group. Dosing is based upon anticipated duration of scan from 30 - 75 minutes and will range from 0.5 mic/kg to 1.25 mcg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: 4 mcg/kg glycopyrrolate will be administered at the start of sedation in the propofol-dexmedetomidine group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 1% Injectable Solution
Description: 1 mg/kg intravenous administration prior to propofol administration
Study: NCT03868098

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ointment
Description: Placebo ointment (vehicle)
Study: NCT03513757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% Injectable Solution
Description: 1 mg/kg intravenous administration prior to propofol administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous Oxide
Description: Inhalation of nitrous oxide may be used for IV placement

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Inhalation of nitrous oxide may be used for IV placement

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Inhalation of sevoflurane may be used for IV placement

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Inhalation of sevoflurane may be used for IV placement
Study: NCT02764710

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-Potassium Clavulanate Combination
Description: Short course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily for a total of 2 doses.~Long course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily up until and including postoperative day 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Potassium Clavulanate Combination
Description: Short course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily for a total of 2 doses.~Long course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily up until and including postoperative day 7.
Study: NCT03688061

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd3-hliNSmut
Description: Attenuated chimpanzee adenovirus (ChAd) vectored vaccine against HCV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd3-hliNSmut
Description: Attenuated chimpanzee adenovirus (ChAd) vectored vaccine against HCV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd3-hliNSmut
Description: Attenuated chimpanzee adenovirus (ChAd) vectored vaccine against HCV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-hliNSmut
Description: Modified Vaccinia Ankara (MVA) vectored vaccine against HCV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-hliNSmut
Description: Modified Vaccinia Ankara (MVA) vectored vaccine against HCV
Study: NCT01953471

Intervention type: OTHER
Intervention: Allergic rhinitis
Description: Questionnaire
Study: NCT03688061

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-hliNSmut
Description: Modified Vaccinia Ankara (MVA) vectored vaccine against HCV
Study: NCT03829163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydraulic Adjustable Walker
Description: The HAW is a based on a conventional walker but has innovative telescoping legs with a leg adjustment assembly that includes at least one valve and at least one tube that delivers hydraulic fluid into the legs and allows a user to control the length of each leg. The legs of the walker are hydraulically adjustable, so that the front legs may be shortened and the back legs extended, or two side legs shortened and the two opposing side legs extended, so as to allow the walker to be securely placed on two different steps. This allows the user to be able to stand on a stair without worrying about sharing the same stair with the device. It also ensures that the height of the walker continues to be the right height for the user to minimize loss of balance.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Walker
Description: A walker consists primarily of a metal frame with four legs which are stabilized by crossbars. These walker frames come in a variety of shapes and sizes; many consist primarily of two inverted U-shaped leg modules connected by crossbars. Regardless of the shape or form of the leg modules, each walker frame forms a 3-sided box with an opening in which the user may stand.
Study: NCT01705743

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane+Nitrous oxide
Description: 60% nitrous oxide +40% oxygen+ Sevoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: 100% oxygen+ Sevoflurane
Study: NCT01389193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibudilast
Description: Ibudilast 40 mg twice daily oral capsules for a duration of 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 40 mg twice daily oral capsules for a duration of 8 weeks
Study: NCT01161368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib, Vinorelbine
Description: Lapatinib 1250mg orally once daily continuously~plus~Vinorelbine 20 mg/m2 intravenously (IV) once weekly \[Days 1 and 8\] for 2 weeks, followed by a rest week in a 3-week cycle.
Study: NCT02223039

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AbGn-168H
Description: AbGn-168H monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AbGn-168H
Description: AbGn-168H monoclonal antibody

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of AbGn-168H
Study: NCT02013310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-0712

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03460405

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vi Polysaccharide Vaccine
Description: 1 dose of Vi Polysaccharide Vaccine
Study: NCT00876538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olesoxime (TRO19622)
Description: 2 capsules of TRO19622 (330 mg) once day with the noon meal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Placebo Control 2 capsules once day with the noon meal
Study: NCT03171779

Intervention type: OTHER
Intervention: Patients approaching the end of their lives
Description: To determine whether the use of simple tools by a primary care team for the early identification of end-of-life patients can improve access to specialized palliative care resources
Study: NCT03460405

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV Vaccine
Description: 1 dose of IPV Vaccine
Study: NCT00911612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam
Description: Welchol (Colesevelam HCL) 1.875 gram twice daily for 12-14 days
Study: NCT03171779

Intervention type: OTHER
Intervention: Patients approaching the end of their lives
Description: To determine whether the use of simple tools by a primary care team for the early identification of end-of-life patients can improve access to specialized palliative care resources

Intervention type: OTHER
Intervention: Patients approaching the end of their lives
Description: To determine whether the use of simple tools by a primary care team for the early identification of end-of-life patients can improve access to specialized palliative care resources
Study: NCT00911612

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert capsule matching the study drug, given twice daily
Study: NCT05691335

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard CXL
Description: Epithelium-off CXL performed by removal of corneal epithelium, instillation of riboflavin onto the cornea followed by UVA corneal irradiation for 30 minutes.
Study: NCT04349280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Description: Participants will receive bintrafusp alfa.
Study: NCT05691335

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Accelerated CXL
Description: Epithelium-off CXL performed by removal of corneal epithelium, instillation of riboflavin onto the cornea followed by UVA corneal irradiation for 5 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transepithelial CXL
Description: Epithelium-on CXL performed by instillation of riboflavin onto the cornea followed by UVA corneal irradiation for 5 minutes.
Study: NCT02617225

Intervention type: BEHAVIORAL
Intervention: DHaAL Intervention
Description: This group handwashing program is for rural elementary schools to institutionalize the practice of handwashing before mid-day meal consumption and after use of toilets by harnessing the theory of social peer pressure.~DHaAL intervention consists of: (1) capacity building of school teachers to implement group handwashing; (2) installing group handwashing station; (3) generating demand among students to wash hands in group; and (4) establishing systems to sustain handwashing infrastructure and behaviors.

Intervention type: BEHAVIORAL
Intervention: DHaAL Intervention
Description: This group handwashing program is for rural elementary schools to institutionalize the practice of handwashing before mid-day meal consumption and after use of toilets by harnessing the theory of social peer pressure.~DHaAL intervention consists of: (1) capacity building of school teachers to implement group handwashing; (2) installing group handwashing station; (3) generating demand among students to wash hands in group; and (4) establishing systems to sustain handwashing infrastructure and behaviors.

Intervention type: BEHAVIORAL
Intervention: DHaAL + CFSS Intervention
Description: In addition to support under DHaAL, several intervention schools receive a more holistic and participatory support that focuses on health, safety, nutrition status, and psychological wellbeing of the children, and thus can also influence handwashing practices (and other WASH facilities). CFSS provides capacity building support and establishes systems to improve school environment, learning outcome, teachers capacity, and physical education for children.
Study: NCT04608175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Treatment of disease by inserting needles along specific pathways or meridians. The placement varies with the disease being treated. It is sometimes used in conjunction with heat, moxibustion, acupressure, or electric stimulation.
Study: NCT01181726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/Norethindrone acetate
Description: 1 mg/0.5 mg Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Activella®
Description: 1 mg/0.5 mg Tablets
Study: NCT03083938

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Omental Roll-up
Description: Using omentum roll-up pancreato-jejunal anastomosis
Study: NCT01035164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 FEDAA1106 (BAY85-8101)
Description: Alzheimer Disease patients: Single intravenous bolus injection of 250 MBq BAY85-8101 on day one of the treatment period, PET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 FEDAA1106 (BAY85-8101)
Description: Healthy volunteers for brain imaging: Single intravenous bolus injection of 250 MBq BAY85-8101 on day one of the treatment period, PET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 FEDAA1106 (BAY85-8101)
Description: Healthy volunteers for whole body imaging: Single intravenous bolus injection of 185 MBq BAY85-8101, whole body PET for evaluation of effective dose, kinetics of BAY85-8101 in blood
Study: NCT03799068

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: suprazygomatic maxillary nerve block
Description: bilateral Suprazygomatic maxillary nerve block is performed before surgery in anaesthetized children, after aseptic preparation of the skin. The patient is in supine position with the head in neutral position. The puncture site is at the frontozygomatic angle, at the junction of the upper edge of the zygomatic arch and the frontal process. A 24G needle is attached to a syringe containing the local anaesthetic. It is advanced to reach the greater wing of sphenoid at approximately 20 mm depth, then withdrawn a few millimetres and redirected toward the nasolabial fold in a 20° forward and 10° downward direction. The progression in the pterygopalatine fossa is 35 to 45 mm. Loss of resistance after passing through the temporalis muscle assisted in determining the puncture depth. After a negative blood aspiration test, the calculated dose of the local anaesthetic is injected on each side.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: surgical site infiltration
Description: peri-incisional infiltration of bupivacaine around the incision site given by the surgeon on an anesthetized patient before the incision is done.
Study: NCT01105026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alveolar Bone Defect Regeneration Following Tooth Extraction
Description: Patients underwent surgery under local anesthesia and minimally invasive periotomy was carried out with a surgical blade. Atraumatic extraction with forceps was performed. The extraction socket was carefully curetted to remove the granulation tissue and was rinsed with a physiologic solution. To evaluate the eligibility of the surgical site, the alveolar walls integrity was checked clinically and by means of extemporaneous peri-apical radiography.~Then, the socket was filled to the bone margin with Inion BioRestore™ (granules size 1 to 2 millimetres). Finally, single interrupted (5-0) sutures were tightened to promote the stability of grafted particles. Ten days after the surgery, sutures were removed.
Study: NCT03233568

Intervention type: DIAGNOSTIC_TEST
Intervention: Indirect calorimetry
Description: Indirect calorimetry will be performed by using an open-circuit calorimeter (Sensor Medics, Italy). Indirect calorimetry is the reference method for energy expenditure determination. A canopy hood covered the patient's head and expired air is extracted by a pump to be analyzed by metabolic cart sensors; flow rate is directly measured with a digital turbine flowmeter. After an overnight fast, patients will asked to lay supine in complete physical rest, not sleeping or talking for approximately 20-25 minutes, at a room temperature ranged between 22 and 24°C. The mean REE for each participant considers the last 15-20 minutes of measurements corresponding to steady state.~Software of calorimeter will be set for minute-by-minute reading report of VO2 (Oxygen flow) and VCO2 (Carbon dioxide flow) measurement.~Parameters obtained by Indirect Calorimetry will be the Resting Energy Expenditure and the Respiratory Quotient (RQ)
Study: NCT01452997

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAI treatment
Description: Ibuprofen 5% gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NSAI treatment
Description: Ibuprofen 5% gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Steroid treatment
Description: Steroid intervention with 0.05% w/w clobetasone butyrate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid treatment
Description: Steroid intervention with 0.05% w/w clobetasone butyrate.
Study: NCT03502863

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital refraction
Description: A web-based application for obtaining the refractive error and visual acuity of each eye, using a computer and a smart phone.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Refraction
Description: Manual refraction and ETDRS chart
Study: NCT01656330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg twice daily
Description: One rivaroxaban 20 mg tablet administered twice a day (b.i.d.) for 4 days (Days 1-4). Interpretation by CTRL: Concentration type = Exact; Number = 20; unit=mg; route: oral use for 4 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg twice daily
Description: One rivaroxaban 20 mg tablet administered twice a day (b.i.d.) for 4 days (Days 1-4). Interpretation by CTRL: Concentration type = Exact; Number = 20; unit=mg; route: oral use for 4 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg twice daily
Description: One rivaroxaban 20 mg tablet administered twice a day (b.i.d.) for 4 days (Days 1-4). Interpretation by CTRL: Concentration type = Exact; Number = 20; unit=mg; route: oral use for 4 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg once daily
Description: One rivaroxaban 20 mg tablet administered once daily on Day 5. Interpretation by CTRL: Concentration type = Exact; Number = 20; unit=mg; route: oral use for 1 day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg once daily
Description: One rivaroxaban 20 mg tablet administered once daily on Day 5. Interpretation by CTRL: Concentration type = Exact; Number = 20; unit=mg; route: oral use for 1 day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg once daily
Description: One rivaroxaban 20 mg tablet administered once daily on Day 5. Interpretation by CTRL: Concentration type = Exact; Number = 20; unit=mg; route: oral use for 1 day.
Study: NCT01597414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab + trastuzumab
Description: Trastuzumab: loading dose of 8 mg/kg of body weight on cycle 1, followed by a maintenance dose of 6 mg/kg every 3 weeks.~Pertuzumab: loading dose of 840 mg on cycle 1, followed by 420 mg for subsequent cycles, every 3 weeks.~if T-DM1: 3.6 mg/kg IV, every 3 weeks.
Study: NCT04023565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perindopril + moxonidine
Description: After 14 days of wash-out period perindopril 10 mg + moxonidine 0.4 mg a day will be prescribed.~If target BP is achieved after 4 weeks, the dosage will remain unchanged (perindopril 10 mg + moxonidine 0.4 mg a day (given as two divided doses).~If target BP is not achieved after 4 weeks, the dosage will increase up to perindopril 10 mg + moxonidine 0.6 mg a day (given as two divided doses).
Study: NCT03342703

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Patients will undergo a standard liver US protocol for approximately 15 minutes.
Study: NCT01656330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Profilnine SD
Description: Single bolus dose of Profilnine SD 50 IU/kg administered by intravenous (IV) injection on Day 5. Interpretation by CTRL: Concentration type = Exact; Number = 50; unit=IU/kg; route: intraveous use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beriplex P/N
Description: Single bolus dose of Beriplex P/N 50 IU/kg administered by intravenous (IV) injection on Day 5 Interpretation by CTRL: Concentration type = Exact ; Number = 50; unit=IU/kg; route : intravenous use
Study: NCT00264810

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: RNS® System implantation
Description: Using standard neurosurgical techniques the surgical team implants the RNS® System, which includes the RNS® Neurostimulator and intracranial NeuroPace® Leads. Up to 4 Leads (Cortical Strips and/or Depth Leads) are placed in or near the epileptogenic focus/foci. The Neurostimulator is placed in the skull and connected to up to 2 Leads. At first the Neurostimulator is programmed to record brain activity (electrographic patterns). The neurologist or neurosurgeon reviews the recorded electrographic patterns and identifies abnormal (epileptiform, or seizure-like) activity. The Neurostimulator is then programmed to detect the abnormal activity.
Study: NCT01597414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab + trastuzumab + metronomic chemotherapy
Description: Pertuzumab and trastuzumab will be administered as in arm A. Cyclophosphamide: daily dose of 50 mg/day. if T-DM1: as in arm A